Share
June 15, 2021
The Lazzaro Spallanzani Institute of Rome, in agreement with the Lazio Region, is launching a study on a sample to verify the efficacy and safety of this new "heterologous" vaccination strategy.
This was announced by Spallanzani regarding the recent indications of a second dose of mRNA vaccine (Pfizer or Moderna) in people who had received a first dose of viral vector vaccine (AstraZeneca).
"The heterologous vaccination strategy - adds the institute - has recently been tested in at least three European countries (England, Spain and Germany), with encouraging results in terms of immunogenicity. Even preliminary observations within our Institute seem to confirm the goodness of this approach ".
Spallanzani, continues the management of the institute, "is starting an evaluation of the ability of the heterologous vaccination scheme (first dose AstraZeneca and second dose Pfizer or Moderna) to generate an adequate immune response, and a number of adverse events comparable with the best data from traditional homologous vaccination schemes. The protocol will be submitted to AIFA for approval over the next few days, and the study can begin as soon as the Agency's authorization is available ".
The institute underlines that "this scientific initiative, endorsed by the Lazio Region, also wants to be a way to give an answer to the questions posed by the population, in order to provide correct and transparent information to citizens, to support an informed decision" .
In the working group Andrea Antinori, Emanuele Nicastri, Enrico Girardi and Concetta Castilletti.
"It is a work aimed at creating greater serenity and greater awareness in the country with respect to a choice of the government that is shared" commented the director of Spallanzani, Francesco Vaia.